Form 4: Hinge Health Director-Affiliated Funds Sell Shares

Funds affiliated with Hinge Health director Elliott Robinson sold over 183,000 shares of Class A Common Stock in two separate transactions.

Summary

• Bessemer Venture Partners X L.P. and Bessemer Venture Partners X Institutional L.P., funds associated with director Elliott Robinson, sold a total of 89,716 shares of Hinge Health Class A Common Stock on February 17, 2026.
• These shares were sold at a weighted average price of $39.929, with individual transaction prices ranging from $39.50 to $40.31.
• An additional 93,743 shares of Class A Common Stock were sold by the same Bessemer Funds on February 18, 2026.
• The shares sold on February 18, 2026, had a weighted average price of $40.358, with prices ranging from $39.535 to $40.855.
• The reporting person, Elliott Robinson, disclaims beneficial ownership of these securities except for his indirect pecuniary interest through his involvement with the Bessemer Funds.
• The transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a slightly negative signal due to the significant volume of shares sold by director-affiliated funds, although the pre-planned nature of the sales under Rule 10b5-1 mitigates some of the immediate concern.

Positives

• The sales were executed at relatively strong price points, with weighted average prices of $39.929 and $40.358, indicating a favorable market for the sellers.
• The transactions were conducted under a Rule 10b5-1(c) plan, suggesting pre-planned sales for diversification or liquidity rather than a reaction to negative internal company developments.

Negatives

• Significant insider selling, even if pre-planned, can sometimes be perceived negatively by the market as it reduces the alignment of interests between insiders and public shareholders.
• The sale of over 183,000 shares by affiliated funds represents a substantial reduction in their holdings, potentially signaling a belief that the stock's near-term upside is limited or that current valuations are attractive for profit-taking.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which primarily reports past transactions.

Management Comments

• The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
• The Reporting Person disclaims beneficial ownership of the securities held by the Bessemer Funds, except to the extent of his pecuniary interest, if any, in such securities by virtue of his indirect interest in the Bessemer Funds.
• This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities.

Industry Context

StockSavvy.ai notes that insider selling, even when pre-planned via a 10b5-1 plan, is a common occurrence for venture capital funds and directors seeking to realize gains or diversify portfolios as companies mature. While not inherently negative, significant sales can sometimes be interpreted by the market as a signal of limited near-term upside, especially if not accompanied by strong company performance or positive news.

Related Party Transactions

• The transactions involve Bessemer Venture Partners X L.P. and Bessemer Venture Partners X Institutional L.P., which are funds affiliated with Elliott Robinson, a director and 10% owner of Hinge Health, Inc.
• Elliott Robinson has an indirect, passive economic interest in the shares held by these Bessemer Funds.

Stakeholder Impact

• Shareholders: The sale of a significant number of shares by director-affiliated funds could lead to a perception of reduced insider confidence, potentially impacting investor sentiment and the stock price.
• Company: No direct operational impact, but market perception of insider selling can influence valuation.

Key Dates

Recommendation

While the insider selling by director-affiliated funds is notable, the transactions were executed under a pre-planned 10b5-1 program, which often indicates portfolio management rather than a reaction to adverse company-specific news. Given the lack of other financial or operational details in this Form 4, a 'hold' recommendation is appropriate, advising investors to monitor future company performance and broader market trends for Hinge Health.

Keywords

Hinge Health, HNGE, SEC Form 4, Insider Selling, Bessemer Venture Partners, Stock Sale, Director Transaction, Beneficial Ownership, Rule 10b5-1